FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313406957> ?p ?o ?g. }

• W4313406957 endingPage "121.01" @default.
• W4313406957 startingPage "121.01" @default.
• W4313406957 abstract "Abstract The chemokine CCL2 (C-C motif ligand 2) is best known for its ability to induce trafficking of immune cells by binding its primary receptor, CCR2. The recruitment of immunosuppressive monocytes by CCL2 promotes cancer in several tumor types. Surprisingly, we previously found an unanticipated protective role for CCL2 signaling in bladder cancer (BC). To determine if CCL2’s effect to suppress bladder tumor growth is dependent on T cells, we examined the effects of α-CCL2 antibody in wild-type versus T cell-deficient mice. The protective effect of CCL2 was lost in T cell-deficient mice and on T cell depletion in wild-type mice. Mixed bone marrow chimera experiments also showed that CCR2+ T cells were preferentially recruited by CCL2 to the bladder compared with CCR2− T cells suggesting that the protective effect of CCL2 in BC is through CCR2+ T cells. Most studies researching chemokines, including CCL2, in cancer assume the chemokine to be completely active and do not consider their different modified states which may be one of the critical reasons behind the failure of chemokines in clinical trials. We show for the first time that bladder tumors induce post-translational nitration of CCL2 and block T cell recruitment to the bladder which is restored by exogenous recombinant (r) CCL2 treatment. However, the chemical nitration of rCCL2 abolished this therapeutic efficacy of rCCL2 and was associated with decreased bladder T cell infiltration and more monocytes infiltration in BC. Our study analyzed the role of nitrated CCL2 in BC which explained certain paradoxes between CCL2 levels and patient outcomes in cancer. We also developed a novel BC treatment strategy using rCCL2 which should lead to effective combinations with existing BC immunotherapies. Supported by (1) the Mays Family Cancer Center at University of Texas Health San Antonio (P30 CA054174), (2) the Roger L. And Laura D. Zeller Charitable Foundation Chair in Urologic Cancer, (3) the Glenda and Gary Woods Distinguished Chair in GU Oncology, (4) the Max & Minnie Tomerlin Voelcker Fund, (5) CDMRP CA170270/P1P2, (6) Bladder Cancer Advocacy Network (BCAN), (7) Research Training Award (RP170345) from the Cancer Prevention & Research Institute of Texas (8) MSTP Program (NIH T32GM113896)" @default.
• W4313406957 created "2023-01-06" @default.
• W4313406957 creator A5016811631 @default.
• W4313406957 creator A5039189970 @default.
• W4313406957 creator A5043639575 @default.
• W4313406957 creator A5074770263 @default.
• W4313406957 creator A5086694072 @default.
• W4313406957 date "2022-05-01" @default.
• W4313406957 modified "2023-09-25" @default.
• W4313406957 title "Nitration of CCL2 disrupts the tumor-protective function of CCL2 in bladder cancer" @default.
• W4313406957 doi "https://doi.org/10.4049/jimmunol.208.supp.121.01" @default.
• W4313406957 hasPublicationYear "2022" @default.
• W4313406957 type Work @default.
• W4313406957 citedByCount "0" @default.
• W4313406957 crossrefType "journal-article" @default.
• W4313406957 hasAuthorship W4313406957A5016811631 @default.
• W4313406957 hasAuthorship W4313406957A5039189970 @default.
• W4313406957 hasAuthorship W4313406957A5043639575 @default.
• W4313406957 hasAuthorship W4313406957A5074770263 @default.
• W4313406957 hasAuthorship W4313406957A5086694072 @default.
• W4313406957 hasConcept C101666144 @default.
• W4313406957 hasConcept C12823836 @default.
• W4313406957 hasConcept C13373296 @default.
• W4313406957 hasConcept C185592680 @default.
• W4313406957 hasConcept C203014093 @default.
• W4313406957 hasConcept C206615009 @default.
• W4313406957 hasConcept C2776107976 @default.
• W4313406957 hasConcept C502942594 @default.
• W4313406957 hasConcept C71924100 @default.
• W4313406957 hasConcept C8891405 @default.
• W4313406957 hasConceptScore W4313406957C101666144 @default.
• W4313406957 hasConceptScore W4313406957C12823836 @default.
• W4313406957 hasConceptScore W4313406957C13373296 @default.
• W4313406957 hasConceptScore W4313406957C185592680 @default.
• W4313406957 hasConceptScore W4313406957C203014093 @default.
• W4313406957 hasConceptScore W4313406957C206615009 @default.
• W4313406957 hasConceptScore W4313406957C2776107976 @default.
• W4313406957 hasConceptScore W4313406957C502942594 @default.
• W4313406957 hasConceptScore W4313406957C71924100 @default.
• W4313406957 hasConceptScore W4313406957C8891405 @default.
• W4313406957 hasIssue "1_Supplement" @default.
• W4313406957 hasLocation W43134069571 @default.
• W4313406957 hasOpenAccess W4313406957 @default.
• W4313406957 hasPrimaryLocation W43134069571 @default.
• W4313406957 hasRelatedWork W2033737664 @default.
• W4313406957 hasRelatedWork W2050746856 @default.
• W4313406957 hasRelatedWork W2059355709 @default.
• W4313406957 hasRelatedWork W2550076081 @default.
• W4313406957 hasRelatedWork W2897645267 @default.
• W4313406957 hasRelatedWork W2986023951 @default.
• W4313406957 hasRelatedWork W3177574928 @default.
• W4313406957 hasRelatedWork W3189664645 @default.
• W4313406957 hasRelatedWork W4281671324 @default.
• W4313406957 hasRelatedWork W4313583862 @default.
• W4313406957 hasVolume "208" @default.
• W4313406957 isParatext "false" @default.
• W4313406957 isRetracted "false" @default.
• W4313406957 workType "article" @default.